Quotient Sciences Launches as the New Global Identity for Quotient Clinical
News Nov 12, 2017
Credit: Quotient Sciences
Quotient Clinical announces its renaming to Quotient Sciences (Quotient), following the acquisitions of Co-Formulate, QS Pharma and SeaView Research. This new identity signifies a global footprint and an extended range of services, and symbolizes the commitment to ensuring a consistent and high-quality experience for customers.
With 700 employees and five operating sites across the United States and the United Kingdom, Quotient is focused on delivering a portfolio of innovative services encompassing formulation development, clinical trial and commercial manufacturing, and clinical pharmacology.
Quotient’s Translational Pharmaceutics® platform integrates formulation development, real-time adaptive GMP manufacturing and clinical research, transforming the traditional industry approach of outsourcing to independent contract development and manufacturing organizations (CDMOs) and contract research organizations (CROs). Translational Pharmaceutics is proven to accelerate development timelines and reduce overall costs.
“We are excited about the future of Quotient Sciences,” said Mark Egerton, CEO, Quotient Sciences. “By integrating services typically found in disparate CDMOs and CROs, we break down barriers and support our customers to improve R&D productivity and accelerate the delivery of new medicines to patients around the world. We have a 30-year track record of service to a global customer base, including large multinational pharmaceutical companies to smaller virtual biotech organizations.”
A new method of selectively binding proteins to nanoparticles has been published. The nanoparticles automatically recognize specific peptides, i.e. small proteins, and enter into highly selective binding with them. Among the model peptides which the researchers examined were amyloids. The researchers hope that the mechanism they have discovered might provide a new approach to treating diseases in which such deposits occur, such as Alzheimer’s disease.READ MORE
International Conference on Clinical Trials & Pharmacovigilance
Feb 28 - Mar 01, 2019